<DOC>
	<DOC>NCT01088321</DOC>
	<brief_summary>The purpose of this study is to compare the incidence rates of infection among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications</brief_summary>
	<brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis of rheumatoid arthritis Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM Age 18 years or older at the time of drug initiation Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation Below 18 years of age at the time of BDM or DMARD initiation Lacking six months of continuous enrollment prior to the initiation of one of the study drugs</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>